
Omeros (OMER) Stock Forecast & Price Target
Omeros (OMER) Analyst Ratings
Bulls say
Omeros Corp has demonstrated a significant clinical advancement with its drug candidate narsoplimab, showing statistically significant survival advantages in patients with transplant-associated thrombotic microangiopathy, which enhances the company's credibility and competitive positioning in the therapeutic market. The encouraging Phase 2 results of Zaltenibart also highlight the safety and potential superiority of emerging treatments, with the possibility of reaching billions in market opportunities if efficacy and safety are proven. Overall, Omeros’s strategic focus on complement-mediated diseases and advancements in clinical evidence strongly supports a positive outlook on the company’s future financial performance.
Bears say
Omeros Corp has experienced considerable operating losses and is not expected to achieve profitability for several more years, indicating a challenging financial outlook. The company's drug candidate, narsoplimab, faces skepticism regarding its potential FDA approval due to an unconventional development trajectory and insufficient clinical data, particularly after more than four years since the Complete Response Letter (CRL). Additionally, Omeros is likely to require substantial further capital for research and development and commercialization efforts, raising concerns about potential ownership dilution for existing shareholders.
This aggregate rating is based on analysts' research of Omeros and is not a guaranteed prediction by Public.com or investment advice.
Omeros (OMER) Analyst Forecast & Price Prediction
Start investing in Omeros (OMER)
Order type
Buy in
Order amount
Est. shares
0 shares